Bio-Techne and Narayana Nethralaya Collaborate on the use of Ella for Ophthalmic Disorder Diagnostic Applications
Retrieved on:
Tuesday, May 18, 2021
b'MINNEAPOLIS, May 18, 2021 /PRNewswire/ --Bio-Techne Corporation (NASDAQ: TECH) today announced a collaboration with Narayana Nethralaya to develop a diagnostic solution for ophthalmology disorders on its ProteinSimple branded, multiplexing immunoassay instrument, Ella.
Key Points:
- b'MINNEAPOLIS, May 18, 2021 /PRNewswire/ --Bio-Techne Corporation (NASDAQ: TECH) today announced a collaboration with Narayana Nethralaya to develop a diagnostic solution for ophthalmology disorders on its ProteinSimple branded, multiplexing immunoassay instrument, Ella.
- The Ella platform , which is currently sold for research use only, allows users to perform high-quality immunoassays with no manual intervention, delivering results in just 90 minutes and requiring only 25 L of sample.
- Narayana Nethralaya plans to conduct diagnostic clinical trials in India, with the aim of filing for regulatory approval using Ella as a diagnostic device for ophthalmic applications.\n"This collaboration with Narayana Nethralaya potentially expands Ella\'s capabilities as a tool for diagnosing ophthalmology disorders in India," commented Chuck Kummeth, Bio-Techne\'s President and Chief Executive Officer.
- "We believe Ella has great potential as a clinical diagnostic system and look forward to pursuing these applications in the future.